Elamipretide injection is an investigational mitochondria-targeted peptide studied for Barth syndrome and mitochondrial myopathy. Here's what research shows.
Elamipretide injection is an investigational, mitochondria-targeted peptide that is given by subcutaneous injection or intravenous infusion in clinical research. It is not FDA-approved for general medical use in the United States, so patients can only receive it through clinical trials, expanded-access programs, or compassionate use. Most published research centers on Barth syndrome, primary mitochondrial myopathy, and a small number of heart and eye conditions linked to mitochondrial dysfunction.
What Is Elamipretide Injection and How Does It Work?
Elamipretide is a synthetic tetrapeptide — four amino acids joined in a short chain — also known in the literature as SS-31, MTP-131, and Bendavia. It is not a hormone, a steroid, or a receptor agonist. Instead, it is designed to accumulate inside mitochondria, the structures that produce most of a cell's energy.
The proposed mechanism centers on cardiolipin, a phospholipid that sits on the inner mitochondrial membrane. Elamipretide binds cardiolipin and appears to stabilize the folded cristae where the electron transport chain assembles. In laboratory and animal models, that stabilization is associated with more efficient ATP production and less leakage of reactive oxygen species.
That mechanism is why researchers describe elamipretide as a mitochondrial protective agent rather than a drug aimed at one symptom. If the theory holds, the same molecule could matter across many conditions where mitochondria underperform — which is both the appeal and the reason results have been mixed.
Elamipretide Dosing and Administration
There is no standard dose of elamipretide injection, because no regulatory agency has approved the drug. Every dose in use comes from a specific study protocol, and protocols are not interchangeable.
Two routes have been tested in human research:
- Subcutaneous injection — the dominant route in rare-disease and ophthalmology trials, typically given once daily.
- Intravenous infusion — used in acute cardiac studies, delivered over a set period with clinical monitoring.
| Research program | Condition studied | Route | Dose used in the protocol |
|---|---|---|---|
| TazPOWER and related Barth syndrome studies | Barth syndrome | Subcutaneous | 40 mg once daily |
| MMPOWER-3 | Primary mitochondrial myopathy | Subcutaneous | 40 mg once daily for 24 weeks |
| ReCLAIM and ReCLAIM-2 | Dry age-related macular degeneration | Subcutaneous | 40 mg once daily |
| Cardiac ischemia-reperfusion studies | Heart attack and heart failure | Intravenous | Weight-based infusion, titrated per protocol |
These figures describe study designs, not treatment recommendations. A dose that appeared tolerable in a 12-patient trial tells you very little about what is safe outside a monitored setting.
Reported Side Effects and Safety
The most commonly reported side effect of elamipretide injection is a local reaction at the injection site — redness, pain, swelling, itching, or bruising. Most of these events were mild to moderate in the trials that reported them.
Other events noted across studies include:
- Headache
- Nausea or diarrhea
- Fatigue
- Dizziness
- Back or limb discomfort
- Minor, temporary changes in routine lab values
Serious adverse events were uncommon, but the study populations were small and follow-up was limited. There is no large post-marketing safety database for elamipretide, because there is no marketed product.
Safety in pregnancy and breastfeeding has not been established. Anyone who is pregnant, nursing, or taking prescription medications should review the risks with a healthcare professional rather than relying on trial summaries.
Is Elamipretide FDA-Approved?
No. Elamipretide injection has not been approved by the FDA for any indication and cannot be prescribed legally in the United States. The sponsor has pursued approval for Barth syndrome, but the agency has not granted it.
Approval status is not a formality. Cleared products come with verified manufacturing, labeled dosing, and mandatory safety reporting. All of that is missing here, which puts elamipretide in a different category from something like vyleesi injection, an FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women.
Material advertised online as elamipretide or SS-31 is normally sold as a research chemical. It is not produced under pharmaceutical quality controls, and its identity, purity, and sterility are rarely verified by an independent lab.
Storage, Reconstitution, and Handling
In clinical trials, elamipretide is supplied as a sterile solution in single-use vials. It is stored refrigerated, protected from light, and never frozen, because the peptide degrades with heat and repeated temperature swings.
Many peptides used in research arrive as a lyophilized powder that must be dissolved before use, and bacteriostatic water for injection — sterile water with 0.9% benzyl alcohol — is the standard diluent for that step. The preservative slows bacterial growth, which is what makes a multi-dose vial practical. People new to lab work often ask what is bacteriostatic water for injection used for, and the short answer is reconstituting powdered peptides and keeping the resulting solution usable for repeated draws.
A few handling points matter:
- That diluent is not intended for intravenous use, because of the benzyl alcohol.
- Multi-dose bottles are commonly sold in 10 mL and 30 mL sizes.
- Suppliers often shorten the name to bac water for injection; it is the same product.
- Never substitute a different diluent unless the protocol specifically calls for it.
Vial formats in research catalogs vary widely. A pt-141 bremelanotide injection 20mg vial is a common multi-dose presentation, while elamipretide research material is usually listed in far smaller quantities. Final concentration depends on both the powder weight and the volume of diluent, so the two have to be matched carefully.
What to Know Before Considering Elamipretide Injection
Elamipretide is a legitimate research compound with a plausible mechanism and a small but real body of human data. That is not the same thing as a proven therapy. Several programs have produced mixed or inconclusive results, and no phase 3 trial has established a clear clinical benefit.
If you are exploring it for yourself or a family member:
- Search ClinicalTrials.gov for recruiting elamipretide studies and review the eligibility criteria.
- Ask a specialist about expanded access or compassionate use, which requires a physician sponsor.
- Treat any unapproved elamipretide vial sold without documentation as a safety risk, not a shortcut.
- Keep your care team informed about everything you are taking, prescribed or not.
Elamipretide injection remains an investigational product, and decisions about it belong with a qualified healthcare professional who knows your medical history.
Frequently Asked Questions
Is elamipretide injection FDA-approved?
No. Elamipretide has not been approved by the FDA for any indication, including Barth syndrome, and it cannot be prescribed in the United States. It is available only through clinical trials or expanded-access programs supervised by a physician.
How is elamipretide injection given?
In rare-disease and eye trials it is given as a once-daily subcutaneous injection, typically 40 mg. In cardiac studies it has been delivered as a weight-based intravenous infusion under clinical monitoring. There is no standard approved dose because the drug is not approved.
What are the most common side effects of elamipretide injection?
Injection site reactions such as redness, pain, and swelling are the most frequently reported side effects. Headache, nausea, diarrhea, fatigue, and dizziness have also been reported. Most events in published trials were mild to moderate, but long-term safety data remain limited.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.